Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorKenneth L. Rock
Estimating the term…
The present invention provides class I MHC-restricted T-T hybridomas, a novel T-T fusion partner therefor and an assay system that allows for the generation and detection of functional, class I MHC restricted T-T hybridomas. The fusion partner comprises a murine BW5147 cell line that has been transfected with a CD8 gene and stably expresses the CD8 gene product. The BW5147 transfectants are used to generate functional, class I MHC restricted T-T hybridomas which are permissive for lymphokine production. Functional class I MHC-restricted T-T hybridomas exhibiting the capability of producing lymphokines are prepared by fusing BW5147 cells expressing CD8 with T lymphocytes activated in a mixed leukocyte reaction (alloreactive T cells) or stimulated with antigen (antigen-stimulated T lymphocytes) and screening the resulting hybrids for the ability to produce lymphokines in response to appropriate antigenic stimulation. Responsiveness of these clones to alloantigen or to antigen-MHC I complexes can be tested by measuring their production of lymphokines, which provides a sensitive and quantitative assay system.
An alloreactive, lymphokine-producing, MHC class 1-restricted T-T hybrid comprising the fusion product of:
An antigen-specific, lymphokine-producing, MHC class I-restricted T-T hybrid comprising the fusion product of:
An MHC Class I-restricted T-T hybridoma comprising the fusion product of a BW5147 cell and an activated T cell, wherein the hybridoma expresses the gene product of an exogenous CD8 gene and secretes the lymphokine IL-2 in response to antigenic stimulation with antigen in association with an appropriate class I MHC molecule.
Dependencies are inferred from the claim text.